The National Equestrian Centre at Flyinge to host European expert meeting on the use of vaccination to prevent strangles in horses

Stockholm, December 11, 2023 – European experts on strangles, a highly contagious and serious infectious disease affecting horses, will on December 13th meet at the National Equestrian Centre at Flyinge to share experiences on the use of vaccination to prevent strangles. Intervacc and its European distribution partner Dechra Pharmaceuticals, supports this gathering of the top European strangles experts and presents a unique opportunity to explore and share the latest advances in strangles prevention and treatment.

Flyinge is one of Sweden's three national equestrian centers focused on developing excellence for the horse sector. It is also one of the world's oldest national studs and has a proud tradition of promoting knowledge to improve the health and performance of horses.

Together with the two other national centers, Wången and Ridskolan Strömsholm, Flyinges mission is to educate future professional equestrians in the sport and leisure aspects of today's horse sector. Teachers and trainers have Olympic credentials, professorships, and deep experience in their areas of expertise and is therefore an ideal venue to host this important meeting on the 13th of December. Our goal is to learn more about how vaccination against strangles is helping to keep horses across Europe healthy. We are dedicated to identifying and communicate new knowledge to improve the control of infectious diseases.

Strangles is an infection of the lymph nodes of the head and neck of horses, which is caused by the bacterium *Streptococcus equi*. Infected horses typically develop fever, nasal discharge, and abscesses in the lymph nodes of the head and neck, which can restrict the airways. In addition to the suffering of affected horses, the disease has severe economic consequences for the horse industry. The disease is highly contagious and over 70 outbreaks of strangles occur in Sweden every year, each usually involving several, and often all, horses on an affected farm.

"This meeting, which is being supported jointly by Intervacc and Dechra Phamaceuticals, will bring together Europe's leading experts on strangles to share experiences on strangles and the use of our vaccine in the field," says Jonas Sohlman, Chief Executive Officer at Intervacc. *"Our belief is that this meeting will help more veterinarians from across Europe to reduce the impact of this dreadful disease."*

For more information please contact:
Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73
E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on December 11, 2023, 10.30 a.m. CET.

About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About Flyinge
At Flyinge Kungsgård, horse operations have been conducted since the 12th century and the facility is today one of Sweden's three national facilities. The four focus areas of the business are education, breeding, horse breeding and events. All national facilities work with preventive infection control measures to fight strangles and other infectious diseases and are therefore a natural choice of place to arrange this meeting with a focus on horse welfare.

About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Dechra’s expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra’s business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com Stock Code: Full Listing (Pharmaceuticals): DPH, LEI: 213800J4UVB5OWG8VX82

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Date Created
2023-12-11